Idebenone
ApprovedCompleted 0 watching 0 views this week📈 Rising
77
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Leber's Hereditary Optic Neuropathy (LHON)
Conditions
Leber's Hereditary Optic Neuropathy (LHON)
Trial Timeline
May 1, 2016 → Mar 29, 2021
NCT ID
NCT02774005About Idebenone
Idebenone is a approved stage product being developed by Santhera Pharmaceuticals for Leber's Hereditary Optic Neuropathy (LHON). The current trial status is completed. This product is registered under clinical trial identifier NCT02774005. Target conditions include Leber's Hereditary Optic Neuropathy (LHON).
Hype Score Breakdown
Clinical
30
Activity
20
Company
2
Novelty
10
Community
12
Clinical Trials (6)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03433807 | Pre-clinical | Completed |
| NCT02771379 | Pre-clinical | Completed |
| NCT02774005 | Approved | Completed |
| NCT00758225 | Phase 2 | Completed |
| NCT00697073 | Phase 3 | Completed |
| NCT00993967 | Phase 3 | Completed |
Competing Products
4 competing products in Leber's Hereditary Optic Neuropathy (LHON)
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Idebenone + Placebo | Santhera Pharmaceuticals | Phase 2 | 44 |
| Idebenone 150 MG Oral Tablet | Santhera Pharmaceuticals | Pre-clinical | 15 |
| Idebenone | Santhera Pharmaceuticals | Pre-clinical | 15 |
| Idebenone + Placebo | Santhera Pharmaceuticals | Phase 3 | 69 |